 open-label dose-ranging trial AL patients persistent lymphadenopathy AIDS-related complex AL lipid mixture vitro activity human immunodeficiency virus HIV cell membrane virion cholesterol depletion multicenter open-label dose-ranging trial Forty men persistent lymphadenopathy AIDS-related complex doses weeks toxicity disease progression immunologic virologic serum lipid profiles compound broad range doses adverse reactions gastrointestinal tract mild severity self-limited duration weight gains treatment weeks cessation therapy disease progression short-term study indication immunorestorative antiviral effect AL T-lymphocyte subset quantitation HIV culture patients HIV antigenemic entry positive antigen levels treatment consequence therapy significant increases serum lipids elevations triglyceride total cholesterol levels conclusion experience group HIV-infected patients doses AL support use compound antiretroviral agent